Tempus AI Announces Collaboration with Predicta Biosciences for Hematologic Sequencing Assay

What happened

Tempus AI has entered a collaboration with Predicta Biosciences to expand commercial access to a co-branded whole-genome sequencing assay, GenoPredicta™, targeting hematologic malignancies and MRD monitoring. This move aims to enhance Tempus's diagnostics portfolio and data collection for its Insights business, aligning with its strategy to scale genomic testing and monetize multimodal clinical data. However, the partnership introduces additional integration complexity, reminiscent of past acquisitions like Ambry and Paige, which have increased operational burdens and delayed GAAP profitability. With Tempus facing large GAAP operating losses of $252.9M in FY2025 and a focus on achieving $65M adjusted EBITDA in FY2026, this expansion adds risk during a critical proof period for operating leverage. Investors should view this as a growth step that does not directly address the core challenge of converting scale into sustainable per-share earnings.

Implication

The partnership may increase Tempus's test volumes in hematologic oncology, potentially boosting Diagnostics revenue and enriching its dataset for Insights licensing, which is crucial for long-term monetization. However, it adds to the integration overhead from recent acquisitions, threatening to delay operating leverage as Tempus strives to narrow FY2025's $252.9M GAAP operating loss. Investors must monitor whether this collaboration accelerates revenue growth without proportionally raising costs, especially given management's guidance for $65M adjusted EBITDA in FY2026 amid rising expenses. Dilution remains a persistent headwind, with structural share issuance capacity and historical SBC expenses of $124.7M in FY2025, undermining per-share value if losses persist. Critical near-term checkpoints include the next quarterly filings for evidence of GAAP loss reduction and avoidance of new primary equity offerings, as the WAIT rating hinges on profitability proof over growth announcements.

Thesis delta

This collaboration does not shift the core investment thesis, which remains focused on Tempus demonstrating operating leverage through narrowing GAAP losses and sustaining high net revenue retention. It is an incremental expansion that supports top-line growth but does not address the profitability overhang or dilution risks highlighted in the DeepValue report. The WAIT rating and monitoring framework stay unchanged, pending clearer evidence from upcoming financial disclosures.